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Background/aim: To evaluate the effect of intravitreal pro re nata (PRN) ranibizumab treatment from the start on the best-corrected
visual acuity (BCVA) and the central retinal thickness (CRT) in macular edema (ME) due to branch retinal vein occlusion (BRVO).
Materials and methods: Patients with ME secondary to BRVO, who were treated on a PRN basis after a single intravitreal ranibizumab
injection, were retrospectively evaluated. The main outcome measures were changes in BCVA and CRT as measured by optical coherence
tomography.
Results: The number of injections over 6 months was 2.43 ± 1.16. The mean BCVA of the patients was 0.84 ± 0.10 logMAR at baseline
and 0.41 ± 0.06 at the 6th month (P < 0.001). Mean BCVA of the ischemic BRVO group was 1.06 ± 0.68 logMAR at baseline and 0.44
± 0.30 logMAR at the 6th month (P < 0.05). Similarly, the mean BCVA of the nonischemic BRVO group was 0.77 ± 0.53 logMAR at
baseline and 0.41 ± 0.36 logMAR at the 6th month (P < 0.05). Between groups, there was no significant difference in mean BCVA at any
examination.
Conclusion: Intravitreal ranibizumab is a safe and effective treatment option for ME due to ischemic and nonischemic BRVO using
PRN from the start.
Key words: Branch retinal vein occlusion, macular edema, ranibizumab

1. Introduction
Retinal vein occlusion is one of the most common types of
retinal vascular diseases (1). Branch retinal vein occlusion
(BRVO) is the most common cause (80%) of all retinal vein
occlusions, which causes retinal edema that can seriously
reduce visual acuity in the case of foveal involvement (2).
Management of macular edema (ME) in BRVO has long
been a challenge for clinicians. The Branch Vein Occlusion
Study Group suggested that grid laser should be used as
the standard treatment in suitable patients with ME, which
has been proven as the only beneficial treatment for years
(3). Recent years witnessed new treatment modalities for
ME secondary to BRVO that were evaluated in randomized
clinical trials. These are intravitreal triamcinolone
injection (4), intravitreal dexamethasone implantation
(5), and intravitreal vascular endothelial growth factor
(VEGF) inhibitors (6,7). One of these anti-VEGF agents
is ranibizumab (Lucentis; Novartis Pharma AG, Basel,
Switzerland), which is a humanized monoclonal antibody
fragment (Fab) that binds all forms of active VEGF-A.
* Correspondence: mcllarkn@yahoo.com
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Previous reports indicated that single-dose intravitreal
anti-VEGF injection was associated with transient
improvement in BRVO (8–11). Moreover, the BRAVO trial
showed the effectiveness of repeated intraocular injections
of ranibizumab in terms of improvement in best-corrected
visual acuity (BCVA) and central retinal thickness (CRT)
in BRVOs (6). In this study, patients with BRVO received
monthly intraocular ranibizumab injections for 6 months.
Although previous studies (12–14) reported the efficacy
of different dosing regimens in BRVO, an established
therapeutic algorithm has not been reported yet. In
addition, these studies did not address the issue of the
ischemic or nonischemic nature of the retinal perfusion.
Moreover, despite promising results with different dose
regimens for bevacizumab injections, clinical trials for
intravitreal ranibizumab injections in BRVO are very
limited (15–21). We aimed to assess the efficacy of pro re
nata (PRN) intravitreal ranibizumab injection from the
start in the treatment of ME in patients with ischemic or
nonischemic BRVO.
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2. Materials and methods
In this retrospective study, we enrolled patients with ME
due to either ischemic or nonischemic BRVO who were
treated with PRN ranibizumab. Patients treated with the
PRN regime from the start and having at least a 6-month
follow-up were included. Patients previously receiving
treatment for retinal vein occlusions such as intravitreal
triamcinolone injection, intravitreal bevacizumab
injection, or laser photocoagulation and those with
conditions preventing any improvement in visual acuity
(e.g., macular ischemia, macular degeneration, epiretinal
membrane) were excluded from the study. Patients who
underwent cataract extraction or other ocular procedures
during the follow-up period were also excluded. Naive
cases with a less than 2-month time interval between the
first BRVO diagnosis and the first injection were included.
The local ethics committee approved the study.
Fluorescein angiography (FA) was performed at the first
visit in order to identify the morphological peculiarities
of the BRVO and assess the status of retinal perfusion.
In the case of severe intraretinal hemorrhage that did
not allow clear identification of the retinal perfusion,
fundus FA was performed after the adequate resolution
of retinal hemorrhage. Extent of capillary nonperfusion
and dropouts of the retinal capillary bed were determined
on FA images. According to FA images, patients were
classified into two main groups: ischemic BRVO and
nonischemic BRVO. Ischemic BRVO diagnosis was made
if the nonperfused area was greater than the 5-disk area.
When the nonperfused area was smaller than the 5-disk
area, patients were classified as nonischemic (22).
Intravitreal ranibizumab was initiated in the patients
with an initial Snellen visual acuity of less than 20/40
and fluid accumulation within the macula secondary to
BRVO. Patients with initial Snellen visual acuity better
than 20/40 were followed for spontaneous resolution and
were not included. Patients were examined monthly and
were treated again if the CRT was ≤300 µm or if there was
persistent ME surrounding the macula that may have led
to visual impairment according to the treating physician’s
evaluation. Intravitreal injection was not performed in the
case of visual impairment without ME. Ranibizumab was
administered intravitreally to all patients at a dose of 0.5
mg/0.05 mL under sterile operating room conditions.
Patients were examined monthly for 6 months. Each
patient had an ophthalmic examination including the bestcorrected Snellen visual acuity (BCVA), biomicroscopic
examination, funduscopic examination, intraocular
pressure (IOP) measurement, and measurement of the
CRT using spectral-domain optical coherence tomography
(OCT) (Optovue; Fremont, CA, USA) at baseline prior
to injection of ranibizumab and at each follow-up visit.
CRT was calculated as the distance between the inner

limiting membrane and the retinal pigment epithelium–
choriocapillaris interface of radial lines through the foveal
area (23). The calipers were set by hand because automated
measurement protocols are more prone to errors (24). To
minimize observer variations, one experienced physician
obtained all scans. BCVA measurements were converted
to the logarithm of the minimum angle of resolution
(logMAR) for statistical analysis.
The main outcomes of this study were functional
changes, mean gain in BCVA, and percentage of cases
having a gain of three or more lines in BCVA. Beside
anatomical alterations, changes in CRT measured by OCT
and mean number of ranibizumab injections were also
evaluated as secondary outcomes.
2.1. Statistical analysis
All data were statistically analyzed using SPSS 16 for Mac
OS X (SPSS Inc., Chicago, IL, USA). Mean ± standard
deviation (SD), median, and minimum and maximum
values are used to describe the quantitative variables.
Frequency and percentages are given for the nominal
data. Normality assumption was checked by Shapiro–Wilk
test and it was found that the data did not show normal
distribution. In order to test the time-based changes
in both BCVA and CRT, the Wilcoxon test was used.
Comparisons between ischemic and nonischemic groups
were performed by Mann–Whitney U test. Frequency and
incidence data were compared using the chi-square test. P
< 0.05 was considered to be statistically significant.
3. Results
A total of 30 eyes of 30 patients with ME secondary to
BRVO were analyzed. The mean age of patients was 58.30
years (SD 9.91; min: 38, max: 85), and 30% of patients were
male. Patient characteristics are shown in the Table.
The mean baseline visual acuity was 0.84 logMAR
(SD 0.10; min: 0.30, max: 1.30). In our study group, there
was a progressive improvement in visual acuity during
the follow-up period. Moreover, this improvement was
significant when compared to baseline visual acuity at all
visits (P < 0.001). The mean logMAR visual acuity at the
6th month of follow-up was 0.41 (SD 0.06; min: 0.30, max:
1.00).
The mean BCVA of the ischemic BRVO group was 1.06
(SD 0.68; min: 0.30, max: 1.30) logMAR at baseline and
0.44 (SD 0.30; min: 0.30, max: 1.00) logMAR at the 6th
month (P < 0.05). Mean BCVA of the nonischemic BRVO
group was 0.77 (SD 0.53 min: 0.30, max: 1.30) logMAR at
baseline and 0.41 (SD 0.36; min: 0.30, max: 1.00) logMAR
at the 6th month (P < 0.05). Between groups, there was no
significant difference in mean BCVA at any examination
time point (P > 0.05) (Figure 1).
In our study group, 3 or more Snellen lines were
gained by 37% of the patients. None of the patients lost ≤3
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Table. Baseline characteristics of the study subgroups.
Ischemic
group (n = 7)

Nonischemic
group (n = 23)

P-value

Male, n (%)

3 (42.8 %)

12 (52.1 %)

0.50

Age, mean

61.42 ± 5.65

60.73 ± 11.02

0.88

Baseline visual acuity, log MAR

1.06 ± 0.68

0.77 ± 0.53

0.33

Mean BCVA at month 6, log MAR

0.44 ± 0.30

0.41 ± 0.36

0.83

Mean CRT at baseline, µm

602.14 ± 250.85

616.43 ± 254.10

0.90

Mean CRT at month 6, µm

259.29 ± 109.33

254.04 ± 103.55

0.73

BCVA: Best-corrected visual acuity; CRT: central retinal thickness.

lines. At the 6th month, 3 of 7 eyes (43%) in the ischemic
group and 8 of 23 eyes (35%) in the nonischemic group
had visual improvement of ≤3 Snellen lines. There was
not a statistically significant difference between groups
regarding visual acuity changes in Snellen lines (P > 0.05).
The changes in Snellen lines in both groups are illustrated
in Figure 2.
Mean baseline macular thickness was 613.10 µm (SD
45.47; min: 275, max: 1390). In the study group, the final
measured mean macular thickness was 255.27 µm (SD
18.80 µm; min: 216, max: 293). At all visits, there was a
statistically significant decrease in macular thickness
compared to baseline (P < 0.001).
In the ischemic BRVO group, CRT improved from
602.14 µm (SD 250.86; min: 393, max: 1110) at baseline to
259.29 µm (SD 109.33; min: 165, max: 470) at the final visit.
In the nonischemic BRVO group, CRT improved from

Figure 1. Mean baseline BCVA changes during follow-up in both
groups. The difference between the groups was not statistically
significant (P > 0.05). BCVA: Best-corrected visual acuity; X-axis,
time (months); Y-axis, mean BCVA (logMAR).
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616.43 µm (SD 254.10; min: 275, max: 1390) at baseline to
254.04 µm (SD 103.56; min: 142, max: 510) at the final visit.
Each group showed a statistically significant reduction in
CRT from baseline during all monthly visits (P < 0.05).
During the follow-up, the mean CRT between the groups
was not statistically significant (P > 0.05, Figure 3).
During the follow-up period, recurrence of ME
occurred in 24 of 30 patients (80%), and 6 (20%) cases had
a complete ME resolution after a single injection. The mean
time interval between first injection and ME recurrence
was 1.16 months (SD: 0.87). ME recurrence was detected
1 month after the first injection in 13 (43%) patients, 2
months after the first injection in 8 (27%) patients, and 3
months after the first injection in 2 (7%) patients. At the
end of the follow-up period, 8 (27%) patients had a CRT
greater than 250 µm in the final OCT scan.
The frequency of complete ME resolution at the 6th
month was not significantly different between groups
(73% [17 of 23] eyes in the nonischemic group versus 71%
[5 of 7] eyes in the ischemic group, P > 0.05).
During the follow-up period, an average of 2.43
injections (SD 1.16; min: 1, max: 5) were administered.

Figure 2. Visual acuity change in Snellen lines in both groups
(chi-square test, P > 0.05).
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Figure 3. Central retinal thickness change during follow-up in
both groups. The difference between groups was not statistically
significant (P > 0.05). CRT, Central retinal thickness; X-axis, time
(months); Y-axis, mean central retinal thickness (µm).

The number of injections over 6 months was 2.2 (SD 1.1;
min: 1, max: 5) in the eyes with nonischemic BRVO and
3.1 (SD 1.2; min: 2, max: 5) in those with ischemic BRVO,
respectively, showing insignificant difference between the
two groups (P > 0.05). The frequency of cases in which only
one injection was performed over the 6-month period was
26% (6 of 23 eyes) in the nonischemic group and 0% in the
ischemic group. Most cases in both the ischemic and the
nonischemic group had two injections (43% in ischemic
and 48% in nonischemic group, respectively; Figure 4).
In our study, we did not observe any endophthalmitis,
retinal detachment, or other complications related to the
procedure. We also did not witness any ocular or systemic
adverse events related to ranibizumab in the study group.
During the follow-up, none of the patients developed any
neovascular complications or needed peripheral laser
photocoagulation.
4. Discussion
In this retrospective study, we investigated the efficacy
of PRN ranibizumab injections from the start for the
treatment of ME in cases of both ischemic and nonischemic
BRVO. PRN treatment from the start yielded favorable
results, both anatomically and functionally. There was a
significant improvement in vision, resulting in a gain of
2 or more lines in 53% of the patients and of 3 or more
lines in 36.6%. Anatomical results were also impressive,
resulting in a substantial decrease in CRT measurements.
ME is a well-known complication related to BRVO,
primarily causing a decrease in vision. VEGF has a
role in the complex and intriguing pathophysiological
mechanisms causing ME via the effects on blood–retinal
barrier breakdown and vascular permeability (19). Several

Figure 4. Frequency of injections during the follow-up period in
both groups (chi-square test, P < 0.05).

clinical studies evaluated the role of anti-VEGF therapy
among patients with retinal vascular diseases with ME
and found a beneficial effect of this treatment on the
progression of ME (6,25–30). A multicenter randomized
study, BRAVO, evaluated the role of 6-month ranibizumab
therapy in BRVO, which revealed a decrease in CRT and
improvement in visual acuity compared to the control
group (25). Despite these beneficial effects of anti-VEGF
therapy on ME, anti-VEGF therapy has also important
disadvantages regarding the short durability of the regimen
and transient therapeutic effects requiring reinjections.
In the present study, the mean baseline logMAR visual
acuity was 0.84 ± 0.10 and there was a significant increase
in visual acuity after the first injection. This increase in
visual acuity continued in the following months and there
was a statistically significant improvement at all visits
compared to the baseline visual acuity. At the 6th month
of follow-up, mean logMAR visual acuity reached 0.41 ±
0.06. In a previous study, Rouvas et al. (20) reported that
baseline logMAR visual acuity improved from 0.74 ±
0.28 to 0.48 ± 0.3. Similarly, Ahn et al. (31) reported an
improvement from 0.61 ± 0.35 logMAR to 0.35 ± 0.30
logMAR. Although mean baseline visual acuity was lower
in our study than in those two studies, visual acuities at the
6th month were similar in our study. Moreover, different
from other studies, we did not apply grid laser rescue
treatment in our study.
In our study, the proportion of patients who gained 3
or more lines at 6 months was lower than in the BRAVO
study (37% vs. 61%, respectively) (25). In the BRAVO
study, monthly injections were administered, the results of
which were thought to reflect the optimal treatment results
under ideal conditions. However, the reported results in
daily practice were lower. In a previous study, Brynskov
et al. (21) reported that 32% of patients gained 3 or more
lines. In that study, the first 3 injections were routinely
performed and later injections were scheduled according
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to PRN injection criteria. Rouvas et al. (20) performed
PRN injection from the beginning and reported that 39%
of patients showed a gain of 3 or more lines. Although the
percentage of patients gaining 3 or more lines in our study
is similar to the results of these aforementioned studies,
the risk of treatment delay should be kept in mind.
The rationale behind our study was mainly based
on the hypothesis that we could gain a similar effect on
visual acuity using fewer injections compared to previous
studies that used a regular injection protocol or an asneeded approach. Similar to our study protocol, fewer
injections were performed in 2 different studies that used
bevacizumab with a mean number of 2.3 and 2.6 injections
in 6 months (18,32). In line with those results, the injection
frequency was 2.4 in our study with ranibizumab and we
found similar improvement in visual acuity and CRT as
in those studies. Although Rouvas et al. (20) found good
anatomic and visual success in a prospective study with
an OCT-guided as-needed treatment regimen using
ranibizumab, they performed a mean of 6 injections
during a 9-month follow-up. In light of those data, lower
injection frequency was found to be associated with similar
functional or anatomic benefit in our study.
Specifically, the BRAVO study investigated the efficacy
of ranibizumab therapy in BRVO patients; however,
that study did not address the issue of the ischemic or
nonischemic nature of the retinal perfusion (25). In our
analysis, we classified the study population into ischemic
and nonischemic groups according to the retinal perfusion
in FA. The clinical end point was similar between the
groups in terms of mean change from baseline CRT and
BCVA at the 6th month. Similarly, Puche et al. (33) did
not find a difference between ischemic and nonischemic
groups regarding the mean change from baseline CRT
and BCVA. However, the ischemic group had a tendency
to receive more injections compared to the nonischemic
group, which did not reach statistical significance. In
addition, eyes in the nonischemic group had a lower mean
baseline logMAR BCVA compared to the ischemic group.
As the visual acuity outcomes in BRVO were reported to
be related to the initial visual acuity at presentation, the
ischemic group in our analysis seemed to get more benefit
from ranibizumab injections (34).
One of the important drawbacks regarding the design
of such studies, including our study, is the initiation of

anti-VEGF therapy irrespective of the duration of patients’
diagnosis. The exact history of the disease might not be
obtained, mostly due to the socioeconomic status of the
patient population, self-reporting issues, or variations in
admissions to different healthcare services. Because the
exact duration of the disease cannot be obtained in such
a retrospective analysis, our study, like several previous
studies, was mainly based on the clinical evaluation of the
clinician (18,35). Moreover, the possibility of spontaneous
resolution during the natural history of the disease should
be considered, which might weaken the exact role of antiVEGF therapy (16). In addition, different from most of
the previous studies, we used a stricter follow-up protocol
with regular monthly visits (18,21).
There are some limitations regarding our study. First,
this study was a retrospective analysis of a single center
and did not have a control group. Second, in addition
to the low number of patients in the study groups, there
was an imbalance regarding distribution of the patients
between groups due to the incidence of ischemic BRVO in
the real-life clinical setting. This might cause low statistical
power. Therefore, further large-scale studies are needed
in order to clarify the effect of PRN ranibizumab therapy
in ischemic and nonischemic BRVO. Third, fundus FA
was performed in the beginning of the study and was
not repeated thereafter due to the possible changes in the
retinal perfusion during follow-up. Finally, although a
PRN from-the-start approach has a lower cost with a high
safety profile, fewer injections might have a potential to
cause treatment delay. Therefore, stricter follow-up should
be considered in such a situation.
In summary, intravitreal ranibizumab injection based
on PRN from the start was an effective and safe modality
for the treatment of ME secondary to BRVO. Our clinical
experience demonstrated that using an as-needed
approach was associated with improvement in both BCVA
and CRT with fewer ranibizumab injections. Moreover, we
observed similar functional and anatomical improvement
in both ischemic and nonischemic patients with similar
injection rates. Despite an increasing body of evidence for
the efficacy of ranibizumab treatment for ME secondary
to BRVO as a PRN from-the-start strategy, an optimal
treatment regimen has not been determined yet. Further
studies are needed to evaluate the optimal treatment
regimen for these patients.
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